AU2017369603B2 - Process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol formulation - Google Patents

Process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol formulation Download PDF

Info

Publication number
AU2017369603B2
AU2017369603B2 AU2017369603A AU2017369603A AU2017369603B2 AU 2017369603 B2 AU2017369603 B2 AU 2017369603B2 AU 2017369603 A AU2017369603 A AU 2017369603A AU 2017369603 A AU2017369603 A AU 2017369603A AU 2017369603 B2 AU2017369603 B2 AU 2017369603B2
Authority
AU
Australia
Prior art keywords
amifostine
gel
solution
aminopropyl
ethanethiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017369603A
Other languages
English (en)
Other versions
AU2017369603A1 (en
Inventor
Céline CLEMENSON
Eric Deutsch
Karine GONZALEZ
Perrine PIVETTE
Xiuping WANG-ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CLEVEXEL PHARMA
Institut Gustave Roussy (IGR)
Universite Paris Saclay
Original Assignee
CLEVEXEL PHARMA
Institut Gustave Roussy (IGR)
Universite Paris Saclay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CLEVEXEL PHARMA, Institut Gustave Roussy (IGR), Universite Paris Saclay filed Critical CLEVEXEL PHARMA
Publication of AU2017369603A1 publication Critical patent/AU2017369603A1/en
Application granted granted Critical
Publication of AU2017369603B2 publication Critical patent/AU2017369603B2/en
Assigned to INSTITUT GUSTAVE ROUSSY, CLEVEXEL PHARMA, Université Paris Saclay reassignment INSTITUT GUSTAVE ROUSSY Request to Amend Deed and Register Assignors: CLEVEXEL PHARMA, INSTITUT GUSTAVE ROUSSY
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/02—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2017369603A 2016-11-30 2017-11-29 Process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol formulation Active AU2017369603B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306582.4 2016-11-30
EP16306582.4A EP3330251A1 (en) 2016-11-30 2016-11-30 Process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol
PCT/EP2017/080881 WO2018100008A1 (en) 2016-11-30 2017-11-29 Process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol formulation

Publications (2)

Publication Number Publication Date
AU2017369603A1 AU2017369603A1 (en) 2019-05-02
AU2017369603B2 true AU2017369603B2 (en) 2021-04-29

Family

ID=57542923

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017369603A Active AU2017369603B2 (en) 2016-11-30 2017-11-29 Process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol formulation

Country Status (11)

Country Link
US (1) US11021442B2 (https=)
EP (2) EP3330251A1 (https=)
JP (1) JP7138104B2 (https=)
KR (1) KR102596798B1 (https=)
CN (1) CN110300742B (https=)
AU (1) AU2017369603B2 (https=)
CA (1) CA3039425A1 (https=)
IL (1) IL266811B (https=)
MX (1) MX386559B (https=)
WO (1) WO2018100008A1 (https=)
ZA (1) ZA201902119B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824880A1 (en) * 2019-11-25 2021-05-26 Clevexel Pharma Freeze-dried powder containing 2-[(3-aminopropyl)amino]ethanethiol and its use for preparing a thermogel
EP4303224A4 (en) * 2021-03-03 2025-02-19 Tohoku University PROTEIN FOLDING AGENTS
CN116283682B (zh) * 2023-02-21 2024-08-02 梯尔希（南京）药物研发有限公司 一种同位素标记的氨磷汀代谢物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU670567A1 (ru) * 1978-02-06 1979-06-30 Предприятие П/Я В-2343 Способ получени дихлоргидрата бета-меркаптоэтил-1,3-пропилендиамина
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239119B1 (en) 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
MXPA03004546A (es) * 2000-11-22 2003-09-10 Rxkinetix Inc Tratamiento de mucositis.
WO2013163423A1 (en) * 2012-04-25 2013-10-31 Musc Foundation For Research Development Compositions and methods for wound healing and tissue repair
FR2994844B1 (fr) * 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU670567A1 (ru) * 1978-02-06 1979-06-30 Предприятие П/Я В-2343 Способ получени дихлоргидрата бета-меркаптоэтил-1,3-пропилендиамина
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DALE M. WALKER ET AL, "WR1065 mitigates AZT-ddI-induced mutagenesis and inhibits viral replication", ENVIRONMENTAL AND MOLECULAR MUTAGENESIS., GB, (2009-07-01), vol. 50, no. 6, doi:10.1002/em.20482, ISSN 0893-6692, pages 460 - 472 *
KOLIO TROEV ET AL, "Immobilization of aminothiols on poly(oxyethyleneH-phosphonate)s and poly(oxyethylene phosphate)s . . .", JOURNAL OF POLYMER SCIENCE, PART A: POLYMER CHEMISTRY, (2007-01-01), vol. 45, no. 7, pp 1349-63 *

Also Published As

Publication number Publication date
IL266811A (en) 2019-07-31
MX386559B (es) 2025-03-19
JP7138104B2 (ja) 2022-09-15
US20200239414A1 (en) 2020-07-30
EP3330251A1 (en) 2018-06-06
KR20190085526A (ko) 2019-07-18
BR112019011006A2 (pt) 2019-10-08
KR102596798B1 (ko) 2023-10-31
BR112019011006A8 (pt) 2023-04-11
IL266811B (en) 2021-10-31
EP3548464A1 (en) 2019-10-09
CN110300742A (zh) 2019-10-01
WO2018100008A1 (en) 2018-06-07
CN110300742B (zh) 2022-02-18
CA3039425A1 (en) 2018-06-07
JP2019535801A (ja) 2019-12-12
AU2017369603A1 (en) 2019-05-02
ZA201902119B (en) 2023-01-25
MX2019006310A (es) 2019-08-12
US11021442B2 (en) 2021-06-01

Similar Documents

Publication Publication Date Title
AU2017369603B2 (en) Process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol formulation
JP2016528162A (ja) がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用
CA2281919A1 (en) Gel delivery vehicles for anticellular proliferative agents
KR101245960B1 (ko) 피리돈카르복시산 유도체를 함유하는 로션제
TWI905111B (zh) 含有對硼苯基丙胺酸之注射液劑
BR112019011006B1 (pt) Composição de termogel, processo para a preparação de uma composição de termogel e usos da composição de termogel
KR101625926B1 (ko) 포스포디에스터라제 타입-5 억제제의 경피 전달을 향상시키는 방법 및 포스포디에스터라제 타입-5 억제제의 경피 전달을 향상시키는 개선된 약학적 조성물
AU2020393375B2 (en) Freeze-dried powder containing 2-[(3-aminopropyl)amino]ethanethiol and its use for preparing a thermogel
KR101985886B1 (ko) 인돌 화합물 및 판테놀을 포함하는 자외선에 의한 피부손상 예방 및 개선용 조성물
ES2280846T3 (es) Formulacion oromucosal y procedimiento para su preparacion.
US11090290B2 (en) Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy
KR102375047B1 (ko) 화학요법의 유해 부작용 예방 및/또는 치료에 사용하기 위한 클로니딘 및/또는 클로니딘 유도체
CN119212680A (zh) 局部组合物和方法
US20230405068A1 (en) Radiation-induced fibrosis treatment

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD CO-PATENTEE UNIVERSITE PARIS SACLAY

HB Alteration of name in register

Owner name: UNIVERSITE PARIS SACLAY

Free format text: FORMER NAME(S): CLEVEXEL PHARMA; INSTITUT GUSTAVE ROUSSY

Owner name: INSTITUT GUSTAVE ROUSSY

Free format text: FORMER NAME(S): CLEVEXEL PHARMA; INSTITUT GUSTAVE ROUSSY

Owner name: CLEVEXEL PHARMA

Free format text: FORMER NAME(S): CLEVEXEL PHARMA; INSTITUT GUSTAVE ROUSSY